Coya Therapeutics, Inc. (COYA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 163,616 | 257,884 | - | |
| Research and development | 3,663,103 | 5,214,076 | 2,223,903 | |
| General and administrative | 2,908,191 | 2,713,890 | 2,219,545 | |
| Depreciation | 6,840 | 6,840 | 6,841 | |
| Total operating expenses | 6,578,134 | 7,934,806 | 4,450,289 | |
| Loss from operations | -6,414,518 | -7,676,922 | -4,450,289 | |
| Other income | 319,541 | 370,165 | 428,871 | |
| Pre-tax loss | -6,094,977 | -7,306,757 | - | |
| Income tax expense | - | - | - | |
| Net loss | -6,094,977 | -7,306,757 | -4,021,418 | |
| Earnings per share, basic | -0.36 | -0.44 | -0.26 | |
| Earnings per share, diluted | -0.36 | -0.44 | -0.26 | |
| Weighted average number of shares outstanding, basic | 16,724,998 | 16,720,511 | 15,221,308 | |
| Weighted average number of shares outstanding, diluted | 16,724,998 | 16,720,511 | 15,221,308 | |